After criticism, HHS reverses plan to cut funds for a landmark study on women's health
In an abrupt reversal, the US Department of Health and Human Services said Thursday that it no longer plans to cut funding for the Women's Health Initiative, a groundbreaking research project focused on preventing disease in older women. The move comes after a wave of concern and criticism about the threat to the longstanding study.
For decades, the initiative – conducted by the National Institutes of Health – has tracked the health of tens of thousands of women to understand how to reduce the risk of cancer, cardiovascular disease, osteoporosis and more in women after menopause.
Seminal findings from the project have included the risks of using certain kinds of hormone therapy for menopause – helping prevent an estimated 126,000 breast cancer diagnoses – and the finding that vitamin D does not help prevent bone loss. The work has led to more than 2,400 scientific publications overall, shaping clinical practice and public health policies across multiple disciplines in the US.
On Monday, the program announced that HHS planned to terminate contracts with its regional centers in September, a move that would 'significantly impact ongoing research and data collection.'
Investigators were awaiting more details Thursday when an update from HHS indicated that plans had changed.
'These studies represent critical contributions to our better understanding of women's health,' HHS told CNN in a statement. 'While NIH initially exceeded its internal targets for contract reductions, we are now working to fully restore funding to these essential research efforts. NIH remains deeply committed to advancing public health through rigorous gold standard research and we are taking immediate steps to ensure the continuity of these studies.'
In a social media post Thursday, HHS Secretary Robert F. Kennedy Jr. said that 'we are not terminating this study.'
'We all recognize that this project is mission critical for women's health,' he wrote.
Experts say that cuts to one of the largest long-term studies on women's health would be a critical loss, jeopardizing invaluable datasets and important studies already in the works.
'We already have serious gaps in women's health that need to be addressed,' Dr. Stephanie Faubion, director of the Mayo Clinic's Women's Health Specialty Clinic in Jacksonville, Florida, and medical director for The Menopause Society, said when the funding cuts were announced.
The Trump administration has identified addressing chronic disease as one of its top priorities, and the Women's Health Initiative has a unique ability to do that.
'When you compare a person to themselves over time, it allows you to much more definitively answer questions about the causes or the factors that contribute to the development of those kinds of diseases that we're all worried about, whether it's heart disease, cancer, dementia, diabetes, fractures, things like that,' said Dr. Rebecca Thurston, a prominent women's health researcher. 'It's the ability to follow a large number of people over time.'
The launch of the Women's Health Initiative in 1992 marked a major shift in the way medical research regarded women, experts say.
'For many years, we thought about women as essentially small men when it came to many chronic diseases,' Thurston said.
There had been a prevailing view that women's health was only about 'bikini medicine,' focused on reproduction and the areas of the body that a bikini covers, she said.
'I think the Women's Health Initiative, and subsequently other studies, have really underscored that things like cardiovascular disease, stroke, dementia and brain aging, they have unique features in women and unique contributors,' Thurston said. 'That means that we really have to study women specifically, that they're not interchangeable with men, and that women's health is more than bikini medicine.'
The historical lack of inclusion of women in medical research is why funding for a project like the Women's Health Initiative is so important, said Dr. Stella Dantas, president of the American College of Obstetricians and Gynecologists.
'WHI centers have become a source of invaluable data and drive research on treatments to address some of the most common health concerns for postmenopausal women, such as heart disease and breast cancer,' she said in a statement.
Thurston says that some major findings from the Women's Health Initiative were being published at a formative time in her career and led to the work she does now, researching menopause, cardiovascular disease and brain aging.
'This study has been answering really important questions on really prevalent health issues,' she said. 'We need to keep the science going. It's so important if we want to prevent heart disease, prevent cancer, keep our bones healthy, keep our brains healthy. We need to be doing this research.'
CNN's Sandee LaMotte contributed to this report.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Howard Stern gives update on Billy Joel's health amid brain condition
NEW YORK — SiriusXM host Howard Stern said he and Billy Joel had dinner after the Piano Man canceled his upcoming tour due to a brain condition, and can assure Joel's fans the rocker isn't on his deathbed. 'He's doing fine,' Stern said on his Tuesday morning program. Joel announced on May 23 that he was taking a break from performing following a recent diagnosis of hydrocephalus, which the National Institutes of Health describes as 'an abnormal buildup of cerebrospinal fluid deep within the brain.' Symptoms can include vomiting, vision problems, difficulty walking and memory loss or other cognitive impairment. Stern said Joel told him a few weeks ago, 'You can tell people, you know, I'm not dying.' According to Stern, Joel wants people to know that while he's not fit to play concerts at the moment, that doesn't mean he's not long for this world. Stern conceded that Joel does face medical challenges, but described him as 'delightful' when the two Long Islanders got together with their wives. The 71-year-old radio personality didn't say where their dinner took place, but claimed he serenaded Joel with a guitar he'd brought to celebrate the Grammy winner's recent 76th birthday. 'He didn't seem real impressed,' Stern confessed. One of the upcoming shows Joel had to cancel was a July 8 gig at Yankee Stadium with Rod Stewart, who himself nixed a Las Vegas performance hours before it was set to begin on Sunday due to illness.
Forbes
2 hours ago
- Forbes
InnovationRx: Trump's Proposed Budget Slashes Biomedical Research
In this week's edition of InnovationRx, we look at the impact of Trump's proposed budget cuts on biomedical research and global health, news from the ASCO cancer meeting, Summit Therapeutics' Maky Zanganeh and more. To get it in your inbox, subscribe here. Getty Images The Trump Administration's detailed budget proposal, released on Friday, slashes spending for research on diseases and global health. If enacted, it would set back the effort to find cures for cancer, Alzheimer's and other diseases and lead to increased deaths and disability worldwide. It would cut the Department of Health and Human Services by about 25%. Within the HHS, the National Institutes of Health faces an even harder hit with a proposed 40% budget cut threatening research on cancer and other diseases. Under the proposed budget, the agency would also consolidate its institutes from 27 to just eight, mostly by combining several institutes and centers into larger departments. An opinion in JAMA called cuts to the NIH 'an $8 trillion health care catastrophe' due to its impact on life expectancy and lost health. Public health is also on the chopping block. The CDC faces a 54% budget cut. Part of those cuts reflect a plan to move some of its work on chronic diseases to a newly formed HHS agency called 'Administration for a Healthy America.' The Trump budget proposal also calls for slashing support for global public health initiatives, such as the President's Emergency Plan for AIDS Relief, a longstanding effort to combat AIDS and HIV, by more than 60%. These proposed cuts would be piled on top of several other major changes that HHS has made to curtail ongoing research. Last week, for example, the Administration terminated a $258 million program aimed at developing a vaccine for HIV, the virus that causes AIDS. Research in this program has also been useful in developing treatments for other conditions, such as snakebites and COVID-19. Last month, the NIH also adopted a new policy banning 'foreign subawards' – meaning that money from NIH grants can't be used to support international scientists who are collaborating with the grant recipient. As a consequence, Nature reported, 'funding will abruptly cease for dozens, if not hundreds, of ongoing trials of experimental drugs and treatments.' Trump's proposed budget is not law, but rather a detailed wish list of the White House's policies. It is up to Congress to determine the federal budget, and lawmakers are only now beginning the annual process to do so. getty Biotech and pharmaceutical companies presented the latest clinical trial data for drugs aimed at combatting the toughest cancers at the American Society for Clinical Oncology annual conference in Chicago. Here are some of the highlights. AstraZeneca reported that its drug Enhertu reduced disease progression or death by 44% when used in combination with the monoclonal antibody pertuzumab for patients with metastatic breast cancer. Patients in the trial survived a median of three years with progression-free disease, the first improvement on a first-line therapy for breast cancer in more than a decade. The company also said that its drug camizestrant, in combination with another family of cancer drugs, reduced the risk of death or disease progression by 56% compared to the current standard of care. This trial was the first to monitor DNA from the tumors with a blood test, rather than with images, to determine whether to change treatment. The ability to do this is 'redefining how breast cancer is treated and followed up,' AstraZeneca oncology head Susan Galbraith told Forbes. Johnson and Johnson reported that 33% of blood cancer patients who received its CAR-T therapy, Carvykti, showed no progression in their cancer over five years after a single infusion of the treatment. The patients in the study had already received other forms of cancer treatment before getting Carvykti. BioNTech said that a high number of mesothelioma patients (a rare and aggressive form of cancer) receiving its drug BNT-327 in a clinical trial responded to the medication, with more than half of the 31 patients seeing their tumors shrink by more than 30%. The Germany-based biotech is exploring use of the drug in a number of tough cancers. It announced on Monday that it agreed to jointly develop and commercialize BNT327 with Bristol Myers Squibb in a deal that could be worth more than $11 billion. Bayer presented new analysis from clinical trials of its prostate cancer drug Nubeqa, finding that the drug improved patient quality of life compared to a placebo. That result followed previous data showing that it reduced risk of disease progression or death by 46% in combination with the current standard of care. On Tuesday, the FDA approved Nubeqa for certain prostate cancer patients. Massachusetts-based biotech Cullinan Therapeutics reported that its small molecule drug candidate, zipalertinib, which targets lung cancer patients with a genetic mutation that prevents common therapies from working, had a 35% response rate. The patients' cancers had already metastasized, but the median progression-free survival rate was more than nine months. About 10% of patients have these mutations, chief medical officer Jeff Jones told Forbes, who said Cullinan is looking to test the drug in broader patient populations as well. The drug, taken as a pill, also had fewer side effects than comparable cancer treatments, he said, making a course of treatment less likely to be discontinued. Pharmaceutical ingredient manufacturer Antheia raised $56 million led by Global Health Investment Corp. at an undisclosed valuation. Cofounder and CEO Christina Smolke told Forbes she hopes to use the funds to expand the company's production of thebaine, a key component of common pain medications. Antheia makes the ingredient using fermentation–similar to the way beer is produced–as opposed to conventional methods, where thebaine is extracted from crops. The Menlo Park, Calif.-based company plans to produce other new products, including oripavine, also used in pain medications, and scopolamine, an ingredient in medications for nausea, vomiting and motion sickness. The fermentation technology allows facilities to be built where they're needed, Smolke said. 'That is going to allow us to rebuild our supply chain and solve issues of resiliency,' she said. AI adoption is accelerating among nurses as they become more comfortable with its use, according to a newly released survey by Incredible Health. Only 38% of nurses now fear AI will hurt their jobs, down from nearly two-thirds last year. Meanwhile 85% of nurses say they want more training on how to use AI in their jobs. Plus: The FDA announced it has begun using AI tools in its internal processes, but NBC News reports that they struggle to perform simple tasks. The Department of Health and Human Services cancelled a contract with Moderna valued at up to $760 million for its development of an mRNA vaccine against potential pandemic viruses, such as avian flu, which is currently circulating in livestock in the United States. The company said that initial clinical trials showed the vaccine candidate was both safe and effective. Moderna said it was exploring options to continue the vaccine's development. HHS Communications Director Andrew Nixon called mRNA technology 'under-tested' in a statement provided to Forbes. 'We are not going to spend taxpayer dollars repeating the mistakes of the last administration, which concealed legitimate safety concerns from the public.' Amesh Adalja, a senior scholar at the Johns Hopkins Center for Health Security, told Forbes that Nixon's comments were 'complete misinformation,' and that mRNA vaccines are an important tool in combatting an infectious disease emergency because of how quickly they can be developed and manufactured. 'You need to have something that's going to be fast,' he said. Forbes profiled Maky Zanganeh, Summit Therapeutics co-CEO, Iranian immigrant and cancer survivor, as part of the America's Richest Self-Made Women list. The Trump Administration has paused appointments for new student visas as it comes up with a plan to review applicant's social media accounts. That means hundreds of newly-minted M.D.'s may not be able to start their residencies. The budget bill that passed the House of Representatives makes significant changes to Medicaid that could result in 7 million people losing their health insurance. The Trump Administration ordered VA doctors and scientists not to publish in journals without first seeking clearance from political appointees, the latest effort to restrict federal researchers' publications. Startup Vivodyne raises $40 million to expand the development of its lab-grown human tissues for use in drug discovery as the FDA and NIH push back on animal testing. (Read our 2023 profile of the company here.) Sanofi plans buy Cambridge, Mass.-based biotech Blueprint Medicines for $9.1 billion in a bid to bolster its rare immunology pipeline. New drug delivery technologies, now undergoing clinical testing, can move medicine to the brain, which may enable better treatments for Alzheimer's and other diseases. The FDA has approved Moderna's new Covid vaccine for adults over 65 and those older than 12 with risk factors. HHS Secretary Robert F. Kennedy Jr., a vaccine critic, has pushed for new restrictions on vaccine eligibility and approval. Young, healthy adults would not be eligible for the new vaccine, despite their inclusion in Moderna's clinical trials. Stat profiled DOGE's Brad Smith, the healthcare entrepreneur behind $67 billion in spending cuts.
New York Post
3 hours ago
- New York Post
M&M's, Skittles and Doritos could be labeled ‘not recommended for human consumption' in Texas
Popular snacks such as Skittles, M&M's and Doritos, and soft drinks like Mountain Dew could soon be labeled 'not recommended for human consumption' if lawmakers in Texas have their way. The Lone Star State's GOP-dominated legislature is moving forward with a bill that would require warning labels on foods sold in the state if they contain ingredients banned or restricted in other countries. The legislation, known as Senate Bill 25, is drawing national attention for targeting well-known snack items that include food dyes prohibited or flagged in regions such as the European Union. 4 Popular snacking items such as Doritos potato chips could be on the verge of being labeled 'not recommended for human consumption' in Texas. Getty Images While these substances are legal in the US, some have been banned or tightly regulated elsewhere due to health concerns. The proposed measure mandates that starting in 2027, manufacturers add clear labels that say,: 'WARNING: This product contains an ingredient that is not recommended for human consumption by the appropriate authority in Australia, Canada, the European Union, or the United Kingdom.'. Supporters of the legislation include Health and Human Services Secretary Robert F. Kennedy Jr., who has made food labeling and ingredient transparency central to his 'Make America Healthy Again' initiative. 'We are committed to protecting public health by ensuring families know what's in their food,' Kennedy has said. 4 Texas' GOP-dominated legislature is moving forward with a bill that would require warning labels on foods and drinks such as Mountain Dew that are sold in the state if they contain ingredients banned or restricted in other countries. The image above shows Bryan Cranston in a Super Bowl commercial from 2020. AP Under Texas law, Abbott has 20 days following the end of the legislative session — which concluded Monday — to sign the measure. A spokesperson for Texas Gov. Greg Abbott said he would carefully review the bill. 'Gov. Abbott will continue to work with the legislature to ensure Texans have access to healthy foods to care for themselves and their families,' press secretary Andrew Mahaleris told Bloomberg News. The bill calls for the warning labels to be printed in a font size at least as large as the smallest type used for existing FDA-required information. The labels must also be placed in a location that is easy to see and designed with enough contrast to stand out on the packaging. A number of major food companies and retail giants, including PepsiCo, Mondelez, Coca-Cola, Conagra Brands and Walmart, expressed concern in a letter to Texas legislators dated May 19. 4 The bill, known as Senate Bill 25, is drawing national attention for targeting well-known snack items like Skittles. Getty Images In the letter, they called on lawmakers to reconsider the bill's scope and potential implications for everyday consumer products. 'As currently written, the food labeling provision in this bill casts an incredibly wide net — triggering warning labels on everyday grocery items based on assertions that foreign governments have banned such items, rather than on standards established by Texas regulators or by the US Food and Drug Administration,' the letter stated. Walmart, which was listed among the signatories, said it is closely following legislative developments that may impact its business and deferred further comment to the Texas Retailers Association. 'Texas retailers and our members including Walmart worked hard on this bill, made some changes, and we'll see how it develops over the next 20 days,' said Gary Huddleston, a grocery industry consultant with the association. Representatives for the companies named in the letter were not immediately available for comment. 4 Representatives for the food industry are urging Texas Gov. Greg Abbott to veto the proposed legislation. Jay Janner/American-Statesman / USA TODAY NETWORK via Imagn Images Other industry-based critics of the bill also argued that it imposes burdensome regulations and could result in consumer confusion. A coalition of food manufacturers and distributors sent a letter to the Texas legislature asking them to reconsider the warning label provision. 'As currently written, the food labeling provision in this bill casts an incredibly wide net — triggering warning labels on everyday grocery items based on assertions that foreign governments have banned such items,' the letter read. John Hewitt, a senior vice president with the Consumer Brands Association, has urged Abbott to veto the bill. 'The ingredients used in the US food supply are safe and have been rigorously studied following an objective science- and risk-based evaluation process,' Hewitt said in a statement. 'The labeling requirements of SB 25 mandate inaccurate warning language, create legal risks for brands and drive consumer confusion and higher costs.'
